From BigGo Finance · BigGo Finance · · 50s
ABL Bio Unveils Cancer Antibody Data at ESMO
ABL Bio shows clinical results for two cancer-targeting antibodies at ESMO conference.
In brief
ABL Bio shows clinical results for two cancer-targeting antibodies at ESMO conference. ABL Bio presents Phase 2 and Phase 1 data for bispecific antibodies targeting gastroesophageal cancer at ESMO. Originally reported by BigGo Finance.
Zivastomig Clinical Data
ABL Bio will present clinical data for Zivastomig (ABL111) at ESMO.
“Zivastomig simultaneously targets claudin 18.2 and 4-1bb”
Zivastomig Phase 2 Trial
Zivastomig targets Claudin 18.2 and 4-1BB for metastatic gastroesophageal cancer.
“It has received fda fast-track and orphan drug designations”
Zivastomig FDA Status
Zivastomig has FDA fast-track and orphan drug designations for gastroesophageal cancer.
“It has received fda fast-track and orphan drug designations”
Razastomig Clinical Data
ABL Bio will present Razastomig (ABL503) data at ESMO.
“Razastomig targets pd-l1 and 4-1bb”
Razastomig Phase 1 Trial
Razastomig is in Phase 1 for monotherapy dose optimization.
“Phase 1 data related to dose optimization of the monotherapy will be released”
ESMO Presentation Dates
Zivastomig data released October 25; Razastomig data released October 23.
“The presentation scheduled for october 25”
What matters most
ABL Bio presents Phase 2 and Phase 1 data for bispecific antibodies targeting gastroesophageal cancer at ESMO.
